Company Profile

Neugenesis Corporation (AKA: Intrexon Corporation)
Profile last edited on: 8/30/2023      CAGE: 47GU3      UEI: MAYPKN53UQ88

Business Identifier: Biotherapeutics for the areas of combinatorial biology and recombinant protein production
Year Founded
1993
First Award
1996
Latest Award
2002
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

849 Mitten Road Suite 102
Burlingame, CA 94010
   (650) 689-2220
   info@neugenesis.com
   www.neugenesis.com
Location: Single
Congr. District: 15
County: San Mateo

Public Profile

In April 2011, Neugenesis Corporation was acquired by Intrexon Corporation, a next generation synthetic biology company. Neugenesis has developed recombinant technologies and production systems related to Neurospora crassa, an exceptionally versatile fungal organism capable of producing a wide spectrum of proteins and metabolites of commercial interest. the firm had been working on development of combinatorial biology technologies such as protein production systems to create libraries for the discovery and improvement of biotherapeutics. Proteins included monomeric, homodimeric and heteromeric proteins. This technology mimics the immune system's ability to generate diversity in antibodies and expands this ability to all heteromeric proteins, not just antibodies. Intrexon also announced that the former Neugenesis facility would become the headquarters for IntrexonÂ’s Industrial Products Division.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 1 NIH $100,000
Project Title: Gene diversification by directed retrotransposition
1996 1 NIH $100,000
Project Title: Production Of Recombinant Proteins In Neurospora Crassa

Key People / Management

  W Dorsey Stuart -- President

  Edward B Cambareri

  C Budd Colby -- Former VP, Business Development

  Douglas C Vann

Company News

There are no news available.